Skip to main content
. 2016 Feb 26;6:22120. doi: 10.1038/srep22120

Figure 3. Cross-validation of cooperative biomarker pairs.

Figure 3

Cell lines with a BRAF mutation from the independent CGP dataset were more sensitive to the BRAF inhibitors PLX4720 (A), left), SB590885 (B), left), or AZ628 (C), left). Higher levels of PPP1R13L, EGFR, IL15RA, or PIM1mRNA expression were associated with decreased drug sensitivity in BRAF mutant cell lines treated with the BRAF inhibitors PLX4720 (A), right), SB590885 (B), right), or AZ628 (C), right). NRAS mutant cell lines from the CGP dataset were more sensitive to the MEK inhibitors CI-1040 (D), left), and NRAS mutant cell lines from the CCLE dataset were more sensitive to the MEK inhibitors AZD6244 (E), left), or PD-0325901 (F), left) in CCLE data, but all NRAS mutant cell lines showed limited therapeutic effects in response to the MEK inhibitors when PIM1 mRNA expression levels were high (D–F), right).